Journal Article

Pharmacokinetic evaluation of intravenous artesunate in adults with uncomplicated falciparum malaria in Kenya: a phase II study

Melendez, Victor, Li, Qigui, Teja-Isavadharm, Paktiya, Ogutu, Bernhards, Hickman, Mark R, Smith, Bryan, Remich, Shon, Otieno, Walter, Weina, Peter J, Miller, Scott R, Polhemus, Mark

2014

Overview

Background Alternatives to treatment for malaria treatment of travellers are needed in the USA and in Europe for travellers who return with severe malaria infections. The objective of this study is to show the pharmacokinetic (PK) profile of intravenous artesunate (AS), which was manufactured under good manufacturing practice (GMP) conditions, in adults with uncomplicated falciparum malaria in Kenya. Methods The PK parameters of intravenous AS manufactured under current cGMP were evaluated after a single dose of drug at 2.4 mg/kg infused over 2 min in 28 adults with uncomplicated Plasmodium falciparum malaria. Plasma concentrations of AS and dihydroartemisinin (DHA) were measured using a validated liquid chromatography–mass spectrometry (LC-MS/MS) methodology. Pharmacokinetic data were analysed with a compartmental analysis for AS and DHA. Results The results suggest there were no drug-related adverse events in any of the patients. After intravenous infusion, the concentration of the parent drug rapidly declined, and the AS was converted to DHA. AS and DHA showed mean elimination half-lives of 0.17 hours and 1.30 hours, respectively. The high mean peak concentration (C max ) of AS was shown to be 28,558 ng/mL while the C max of DHA was determined to be 2,932 ng/mL. Significant variability was noted in the PK profiles of the 28 patients tested. For example, C max values of AS were calculated to range from 3,362 to 55,873 ng/mL, and the C max value of DHA was noted to vary from 1,493 to 5,569 ng/mL. The mean area under the curve (AUC) of AS was shown to be approximately half that of DHA (1,878 ng·h/mL vs 3,543 ng·h/mL). The DHA/AS ratio observed was 1.94 during the one-day single treatment, and the AUC and half- life measured for DHA were significantly larger and longer than for AS. Conclusions Intravenous AS can provide much higher peak concentrations of AS when compared to concentrations achieved with oral therapy; this may be crucial for the rapid elimination of parasites in patients with severe malaria. Given the much longer half-life of DHA compared to the short half-life of AS, DHA also plays a significant role in treatment of severe malaria.

• Publisher: BioMed Central,BioMed Central Ltd,Springer Nature B.V
• Subject: Activation, Metabolic / Adult / Aged / Analysis / Antimalarials - administration & dosage / Antimalarials - adverse effects / Antimalarials - blood / Antimalarials - pharmacokinetics / Antimalarials - supply & distribution / Antimalarials - therapeutic use / Artemisinins - administration & dosage / Artemisinins - adverse effects / Artemisinins - blood / Artemisinins - pharmacokinetics / Artemisinins - supply & distribution / Artemisinins - therapeutic use / Artesunate / Atovaquone - therapeutic use / Biomedical and Life Sciences / Biomedicine / Chromatography, Liquid / Clinical trials / Drug Combinations / Drug Compounding - standards / Drug Monitoring / Entomology / Female / Half-Life / Humans / Infectious Diseases / Infusions, Intravenous / Kenya / Liquid chromatography / Malaria / Malaria, Falciparum - blood / Malaria, Falciparum - drug therapy / Male / Mass Spectrometry / Medical research / Medicine, Experimental / Methods / Microbiology / Middle Aged / Mortality / Parasites / Parasitology / Pharmacokinetics / Plasmodium falciparum / Proguanil - therapeutic use / Public Health / Reticulocytes - drug effects / Studies / Travelers / Tropical Medicine / Vector-borne diseases / Young Adult